Edition:
United States

Eagle Pharmaceuticals Inc (EGRX.OQ)

EGRX.OQ on NASDAQ Stock Exchange Global Market

67.39USD
21 Sep 2018
Change (% chg)

$-1.62 (-2.35%)
Prev Close
$69.01
Open
$68.87
Day's High
$68.87
Day's Low
$64.77
Volume
721,993
Avg. Vol
89,910
52-wk High
$85.66
52-wk Low
$48.94

Chart for

About

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its... (more)

Overall

Beta: 1.26
Market Cap(Mil.): $1,014.62
Shares Outstanding(Mil.): 15.06
Dividend: --
Yield (%): --

Financials

  EGRX.OQ Industry Sector
P/E (TTM): 31.77 30.48 32.69
EPS (TTM): 2.12 -- --
ROI: 16.02 13.04 12.72
ROE: 18.91 14.99 14.85

BRIEF-Eagle Pharmaceuticals Gets Final FDA Approval For Bendamustine Hydrochloride Ready-To-Dilute Solution In 500Ml Admixture

* EAGLE PHARMACEUTICALS INC GRANTED FINAL FDA APPROVAL FOR BENDAMUSTINE HYDROCHLORIDE READY-TO-DILUTE SOLUTION IN A 500ML ADMIXTURE

May 16 2018

BRIEF-Eagle Pharmaceuticals Reports Q1 Adjusted Non-GAAP Earnings Per Share Of $0.53

* EAGLE PHARMACEUTICALS, INC. REPORTS FIRST QUARTER 2018 RESULTS

May 10 2018

BRIEF-Eagle Pharmaceuticals Says CEO Scott Tarriff's 2017 Total Compensation Was $8.04 Mln

* EAGLE PHARMACEUTICALS INC SAYS CEO SCOTT TARRIFF'S 2017 TOTAL COMPENSATION WAS $8.04 MILLION VERSUS $7.15 MILLION IN 2016 – SEC FILING Source : https://bit.ly/2HK04hV Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 30 2018

BRIEF-Eagle Pharmaceuticals’ Vasopressin ANDA Accepted For Filing By The FDA

* EAGLE PHARMACEUTICALS’ VASOPRESSIN ANDA ACCEPTED FOR FILING BY THE FDA

Apr 16 2018

BRIEF-Eagle Pharmaceuticals - Announced Co's Eagle Biologics Division Has Been Issued A New Patent

* EAGLE PHARMACEUTICALS - ANNOUNCED CO'S EAGLE BIOLOGICS DIVISION HAS BEEN ISSUED A NEW PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 27 2018

Earnings vs. Estimates